Furthermore, a novel FTO inhibitor, Dac51, facilitated the effect of PD-L1 blockade therapy for better tumor control, showing slower growth and longer overall survival by increasing T cell infiltration, indicating a potent strategy to synergistically improve the immune response in melanoma and NSCLC (167). Here, CD274 is linked to melanoma.